MitoQ is a laboratory-made coenzyme Q10 sold as a supplement. The strongest human signal is better artery widening after weeks of use in middle-aged and older adults whose vessels already widen poorly. Vessel-function test, not heart attacks or deaths. Stomach upset is the main reported harm at higher doses. Not a proven lengthening of life or a general performance aid. (Full Review)

Protocol

Seals/Boulder vascular protocol

20 mg once daily for 6 weeks

Oral mitoquinol mesylate, taken with breakfast, in older adults with baseline flow-mediated dilation below 6%.

Commercial MitoQ Ltd protocol

Two 5 mg capsules (10 mg)

With water 30 minutes before food, framed as a morning habit for at least 90 days; a marketing schedule, not a trial dose.

Time of day

Morning dosing

Matches both the Boulder trial (with breakfast) and the commercial empty-stomach directions; no evening-versus-morning comparison exists.

Time to effect

Endothelial Function

6 weeks

Dilation was measured at 6 weeks of 20 mg daily.

Walking Capacity in Peripheral Artery Disease

Single 80 mg dose

Walking distance and walking time improved after one 80 mg dose.

Liver Enzyme Reduction in Chronic Hepatitis C

28 days

Alanine aminotransferase fell from baseline to day 28 at 40 mg and 80 mg daily.

Benefits

High: Endothelial Function

Medium: Walking Capacity in Peripheral Artery Disease; Liver Enzyme Reduction in Chronic Hepatitis C; Training-Related Peak Power

Low: Aortic Stiffness

Speculative: Lifespan Extension

Contraindications

Pregnancy and lactation

Planned conception during use

Known hypersensitivity to mitoquinol, mitoquinone, or capsule excipients

Children and adolescents

Key Interactions

Over-the-counter analgesics and acid suppressors (pain-relieving and acid-reducing medicines such as ibuprofen, acetaminophen, omeprazole)

Vitamin C and vitamin E (high-dose combined antioxidants)

Coenzyme Q10 and ubiquinol

Warfarin and other vitamin K antagonists (blood-thinning medicines such as warfarin, acenocoumarol)

P-glycoprotein inhibitors (clarithromycin, verapamil, grapefruit juice)

Other mitochondria-targeted agents (elamipretide, SkQ1)

Risk & Side Effects

High: Gastrointestinal Intolerance at Higher Doses

Medium: Acute Reduction in Maximal Aerobic Capacity; Delayed Recovery of Eccentric Force After Muscle-Damaging Exercise

Speculative: Mitochondrial Uncoupling or Pro-Oxidant Action at High Concentration

Monitoring

Marker	Target	Why
Flow-mediated dilation	≥6% (trial entry used <6% as impaired)	Primary vascular endpoint in human MitoQ trials
Carotid-femoral pulse-wave velocity	<7.60 m/s (Framingham "healthy vascular aging")	Stiffness endpoint in the Boulder stiff subgroup
Oxidized low-density lipoprotein	Change from the person's own baseline; no established functional target	Circulating oxidative-stress marker that fell 13% at 6 weeks
Alanine aminotransferase	Functional aim often <20–25 U/L	Only human "liver" signal is a short hepatitis C enzyme drop
Estimated glomerular filtration rate	Track change from baseline	Documents kidney safety rather than a benefit
Resting systolic blood pressure	Functional aim often <120 mm Hg	Contextual vessel load; not a consistent MitoQ endpoint

Cadence: Baseline, then 6 weeks, 12 weeks if use continues, then every 6–12 months

Qualitative Assessment

Morning gastrointestinal comfort in the first two weeks
Tolerance of usual aerobic sessions (no unexpected early fatigue)
Recovery after unaccustomed lowering or downhill work
Subjective energy, treated as secondary to the vessel measurements

MitoQ for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment